Allianz Asset Management
COGT icon

Allianz Asset Management’s Cogent Biosciences COGT Stock Holding History

Allianz Asset Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$677K Sell
17,500
-15,100
-46% -$528K ﹤0.01% 1954
2026
Q1 		$1.25M Hold
32,600
– – ﹤0.01% 1677
2025
Q4 		$1.16M Buy
+32,600
New +$916K ﹤0.01% 1679

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Allianz Asset Management's COGT Position: Q2 2026 in Review

Allianz Asset Management reduced its Cogent Biosciences (COGT) stake by 46% in Q2 2026, selling an estimated $528K and leaving 17,500 shares worth $677K. The position accounts for ﹤0.01% of the portfolio, ranked #1954.

Allianz Asset Management first reported a position in COGT in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.25M in Q1 2026. 324 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Allianz Asset Management held 17,500 shares of Cogent Biosciences worth $677K as of Q2 2026.
  • Allianz Asset Management sold 15,100 Cogent Biosciences shares in Q2 2026, an estimated $528K.
  • Cogent Biosciences made up ﹤0.01% of Allianz Asset Management's portfolio in Q2 2026, its #1954 holding.
  • Allianz Asset Management first reported a position in Cogent Biosciences in Q4 2025 and has held it in 3 quarters since.
  • Allianz Asset Management's Cogent Biosciences position peaked at $1.25M in Q1 2026.
  • 324 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Allianz Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.